# Novilla Pharmaceuticals

> Novilla Pharmaceuticals is a Cambridge, Massachusetts biotech using a proprietary AI drug-delivery platform to redesign how established drugs reach the body. By pairing chemical-thermodynamic machine learning with deep eutectic solvents and ionic liquids, Novilla formulates non-invasive transdermal creams that concentrate a drug at its site of action while minimizing systemic exposure. Its lead candidate, NOV-1776 for gout flares, reported a 212% increase in efficacy over standard of care with under 1% systemic exposure and no GI adverse events in early human trials, positioning the company as a non-addictive alternative in pain care.

- **Founded:** 2019
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Dr. Shashidhar Kori (Co-Founder & CEO), Dr. Eric Fossel (Co-Founder), Ajay Kori (Co-Founder & Managing Director)
- **Team size:** ~15 employees
- **Products:** AI Drug-Delivery Platform, NOV-1776, Non-invasive transdermal cream delivery
- **Notable:** NOV-1776 reported 212% increase in efficacy over standard of care in early human trials., Demonstrated under 1% systemic exposure and 0% GI adverse events versus high GI-issue prevalence for standard of care., Lead candidate described as Phase II ready for gout flares.

## Products & services

- **AI Drug-Delivery Platform** — Chemical-thermodynamic machine learning that screens billions of formulation combinations in silico to identify the one or two that penetrate tissue far deeper than previously possible, using deep eutectic solvents and ionic liquids.
- **NOV-1776** — Lead AI-designed drug candidate for gout flares. Reported a 212% increase in efficacy over standard of care with under 1% systemic exposure and 0% GI adverse events in early human trials; described as Phase II ready.
- **Non-invasive transdermal cream delivery** — A topical delivery mechanism that concentrates therapeutic levels of an established drug locally at the site of action while avoiding systemic exposure.

## Achievements

- NOV-1776 reported 212% increase in efficacy over standard of care in early human trials.
- Demonstrated under 1% systemic exposure and 0% GI adverse events versus high GI-issue prevalence for standard of care.
- Lead candidate described as Phase II ready for gout flares.
- Raised approximately $9M in total funding.
- Built a proprietary chemical-thermodynamic machine learning platform for formulation screening.

## Latest updates

- **2025-06** — Featured as an exhibitor at the BIO International Convention 2025.
- **2021-11** — Most recent funding round ($6M; Series A), part of ~$9M total raised, with Hammerstone Capital as institutional investor.

## Links

- Website: https://novilla.com
- LinkedIn: https://www.linkedin.com/company/novilla-pharmaceuticals

---

Profile page: https://yespress.io/novilla-pharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-06-13